124 related articles for article (PubMed ID: 14713802)
1. Can higher doses of oxybutynin improve efficacy in neurogenic bladder?
Bennett N; O'Leary M; Patel AS; Xavier M; Erickson JR; Chancellor MB
J Urol; 2004 Feb; 171(2 Pt 1):749-51. PubMed ID: 14713802
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
3. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.
O'Leary M; Erickson JR; Smith CP; McDermott C; Horton J; Chancellor MB
J Spinal Cord Med; 2003; 26(2):159-62. PubMed ID: 12828295
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
[TBL] [Abstract][Full Text] [Related]
5. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
Malone-Lee J; Shaffu B; Anand C; Powell C
J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
[TBL] [Abstract][Full Text] [Related]
6. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
Fader M; Glickman S; Haggar V; Barton R; Brooks R; Malone-Lee J
J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence.
Radomski SB; Caley B; Reiz JL; Miceli PC; Harsanyi Z; Darke AC
Curr Med Res Opin; 2004; 20(2):249-53. PubMed ID: 15006020
[TBL] [Abstract][Full Text] [Related]
9. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
[TBL] [Abstract][Full Text] [Related]
10. A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women.
Gittelman M; Weiss H; Seidman L
J Urol; 2014 Apr; 191(4):1014-21. PubMed ID: 24231837
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G
J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study.
Aaron LE; Morris TJ; Jahshan P; Reiz JL
Curr Med Res Opin; 2012 Aug; 28(8):1369-79. PubMed ID: 22769237
[TBL] [Abstract][Full Text] [Related]
13. Prospective open label study of solifenacin for overactive bladder in children.
Bolduc S; Moore K; Nadeau G; Lebel S; Lamontagne P; Hamel M
J Urol; 2010 Oct; 184(4 Suppl):1668-73. PubMed ID: 20728124
[TBL] [Abstract][Full Text] [Related]
14. Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study.
Yoo DS; Han JY; Lee KS; Choo MS
Int J Clin Pract; 2012 Feb; 66(2):132-8. PubMed ID: 22188444
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
[TBL] [Abstract][Full Text] [Related]
17. Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review.
Guerra LA; Moher D; Sampson M; Barrowman N; Pike J; Leonard M
J Urol; 2008 Sep; 180(3):1091-7. PubMed ID: 18639290
[TBL] [Abstract][Full Text] [Related]
18. Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.
Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
Low Urin Tract Symptoms; 2016 Sep; 8(3):150-8. PubMed ID: 27619779
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.
Dmochowski RR; Davila GW; Zinner NR; Gittelman MC; Saltzstein DR; Lyttle S; Sanders SW;
J Urol; 2002 Aug; 168(2):580-6. PubMed ID: 12131314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
